case_images: PMC10511119_01
case_images: PMC10511119_02
case_images: PMC10511119_03
case_images: Clinical history of the patient and PET/CT images of patient while on Ripretinib therapy.. Representative serial PET/CT imaging studies from baseline (prior to initiation of ripretinib) to immediately before her second surgery are illustrated in the figure. The MIP images from PET are illustrated in the top row and fused PET/CT images are illustrated in subsequent rows. The baseline PET/CT (a-c) shows multiple FDG-avid peritoneal/retroperitoneal implants of which 3 target areas are annotated (dominant lesion in the left upper quadrant is annotated with blue arrow and two smaller lesions are annotated with white arrows). Follow-up PET/CT at 5 weeks (d-f) shows decreased size and uptake of all implants including the target lesions. Follow up PET/CT at 26 weeks (g-i) shows recurrent uptake in two smaller target lesions near the midline (white arrows) and persistent response in the dominant lesion in the left upper quadrant (blue arrow). Only one of the two smaller lesions is illustrated with axial fused PET/CT images c, f and i. These two smaller lesions showing recurrent uptake were resected at ~29 weeks. Follow-up PET/CT images after initial surgery and 35 weeks from baseline (j, k) showed recurrent uptake in the previously responding dominant left upper quadrant implant (blue arrows), which resolved on the subsequent follow-up PET/CTs at 43 weeks (l, m) and 75 weeks (n, o). The disease then slowly progressed over the next few studies with eventual development of 3 new areas of uptake illustrated on 138 week follow-up PET/CT (p-r). The new sites of uptake are annotated with green arrows. Note that the dominant left upper quadrant implant shows persistent response at the 138 week follow-up study (blue arrow). The patient then underwent second surgical resection and subsequent follow-up imaging (not illustrated here) showed residual disease that further responded to treatment and then progressed with development of new liver metastases.
case_images: oncoscience-10-586-g001.jpg
case_images: PMC10511119_04_oncoscience-10-586-g001.jpg
case_images: F1
case_images: Patient was taken off ripretinib and enrolled onto a clinical trial with another investigational agent (Figure 1).
case_images: PMC10511119_04
case_images: Clinical history of the patient and PET/CT images of patient while on Ripretinib therapy.. Representative serial PET/CT imaging studies from baseline (prior to initiation of ripretinib) to immediately before her second surgery are illustrated in the figure. The MIP images from PET are illustrated in the top row and fused PET/CT images are illustrated in subsequent rows. The baseline PET/CT (a-c) shows multiple FDG-avid peritoneal/retroperitoneal implants of which 3 target areas are annotated (dominant lesion in the left upper quadrant is annotated with blue arrow and two smaller lesions are annotated with white arrows). Follow-up PET/CT at 5 weeks (d-f) shows decreased size and uptake of all implants including the target lesions. Follow up PET/CT at 26 weeks (g-i) shows recurrent uptake in two smaller target lesions near the midline (white arrows) and persistent response in the dominant lesion in the left upper quadrant (blue arrow). Only one of the two smaller lesions is illustrated with axial fused PET/CT images c, f and i. These two smaller lesions showing recurrent uptake were resected at ~29 weeks. Follow-up PET/CT images after initial surgery and 35 weeks from baseline (j, k) showed recurrent uptake in the previously responding dominant left upper quadrant implant (blue arrows), which resolved on the subsequent follow-up PET/CTs at 43 weeks (l, m) and 75 weeks (n, o). The disease then slowly progressed over the next few studies with eventual development of 3 new areas of uptake illustrated on 138 week follow-up PET/CT (p-r). The new sites of uptake are annotated with green arrows. Note that the dominant left upper quadrant implant shows persistent response at the 138 week follow-up study (blue arrow). The patient then underwent second surgical resection and subsequent follow-up imaging (not illustrated here) showed residual disease that further responded to treatment and then progressed with development of new liver metastases.
case_images: oncoscience-10-586-g001.jpg
case_images: PMC10511119_04_oncoscience-10-586-g001.jpg
case_images: F1
case_images: Patient was taken off ripretinib and enrolled onto a clinical trial with another investigational agent (Figure 1).